A pediatric case of acute myeloid leukemia with KMT2A gene rearrangement t(10;11) and 16p11.2 microdeletion syndrome

Pediatr Blood Cancer. 2021 Feb;68(2):e28764. doi: 10.1002/pbc.28764. Epub 2020 Oct 15.

Authors

Keisuke Abe¹, Leah Dowsett¹, Randal Wada¹, Kelley Hutchins¹

Affiliation

¹ Department of Pediatrics, University of Hawai'i, John A. Burns School of Medicine, Honolulu, Hawaii.

PMID: 33058483
DOI: 10.1002/pbc.28764

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Autistic Disorder / genetics*
Child
Chromosome Deletion
Chromosome Disorders / genetics*
Chromosomes, Human, Pair 16 / genetics
Cytarabine / therapeutic use
Daunorubicin / therapeutic use
Etoposide / therapeutic use
Female
Hematopoietic Stem Cell Transplantation
Histone-Lysine N-Methyltransferase / genetics*
Humans
Intellectual Disability / genetics*
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Mitogen-Activated Protein Kinase 3 / genetics*
Myeloid-Lymphoid Leukemia Protein / genetics*
Vault Ribonucleoprotein Particles / genetics*

Substances

Antineoplastic Agents
KMT2A protein, human
Vault Ribonucleoprotein Particles
major vault protein
Cytarabine
Myeloid-Lymphoid Leukemia Protein
Etoposide
Histone-Lysine N-Methyltransferase
MAPK3 protein, human
Mitogen-Activated Protein Kinase 3
Daunorubicin

Supplementary concepts

16p11.2 Deletion Syndrome